A pivotal Phase 3 trial has shown that a new combination treatment can significantly reduce the risk of death among prostate cancer patients by almost 33%.
Results from the Phase 3 ARASENS clinical trial have shown that the use of the oral androgen receptor inhibitor (ARi) darolutamide, with ADT and docetaxel, significantly reduced the risk of death by 32.5%, compared to docetaxel plus ADT in patients with metastatic hormone-sensitive prostate cancer (mHSPC).
https://www.pharmatimes.com/news/data_day_trial_results_deliver_hope_for_prostate_cancer_patients_1387889Adding Darolutamide: New SOC for Metastatic Prostate Cancer:
--------------------------------------------
https://www.medscape.com/viewarticle/968870